#sickle-cell-disease

#sickle-cell-disease

Insurers' refusal to cover innovative gene therapies for conditions like sickle cell disease jeopardizes patient access, necessitating creative financing solutions.

Keenan 'Special' Bristol's film highlights the struggles of those with sickle cell disease and the need for compatible blood donations.

Blood donations in London have significantly dropped post-December, impacting availability for critical blood types, especially among communities needing specific support.

Brixton's new blood donor center has saved approximately 11,000 lives by collecting over 3,000 blood units in three months.

Casgevy is the first approved CRISPR gene-editing treatment available, but complexities hinder widespread patient access.

The first CRISPR-based treatment, Casgevy, has been approved for sickle cell disease and beta thalassemia, marking a significant advance in gene-editing therapies.

Sickle cell gene-editing therapy to be available on the NHS for £1.65m, promising a potential cure for patients.